Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas

[1]  Pieter Wesseling,et al.  cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading , 2020, Brain pathology.

[2]  P. Lowenstein,et al.  Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1 , 2020, Neuro-oncology advances.

[3]  G. Reifenberger,et al.  cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas , 2020, Acta Neuropathologica.

[4]  Lilian Besson,et al.  CamDavidsonPilon/lifelines: v0.23.8 , 2020 .

[5]  Wei-wei Wang,et al.  IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations , 2019, Brain pathology.

[6]  E. Holland,et al.  Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma. , 2019, Journal of neuropathology and experimental neurology.

[7]  F. Ducray,et al.  PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas , 2019, Neuro-Oncology.

[8]  F. Ducray,et al.  CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. , 2019, Neuro-oncology.

[9]  E. Holland,et al.  Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. , 2019, Neuro-oncology.

[10]  David T. W. Jones,et al.  Novel, improved grading system(s) for IDH-mutant astrocytic gliomas , 2018, Acta Neuropathologica.

[11]  Hideo Nakamura,et al.  Prognostic relevance of genetic alterations in diffuse lower-grade gliomas , 2018, Neuro-oncology.

[12]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[13]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[14]  Pieter Wesseling,et al.  IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO , 2015, Acta Neuropathologica.

[15]  I. Pollack,et al.  Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. , 2012, Neuro-oncology.

[16]  Simion I. Chiosea,et al.  Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas , 2008, Modern Pathology.

[17]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..